Our innovative pipeline of investigational siRNA therapies is currently focused on diseases with high unmet need in several therapeutic areas. Additionally, we will follow the science and are continually looking at how we can use our technology platform to help new patient populations.
Preclinical
Phase I
Phase II
Phase III
RARE
Divesiran
(TMPRSS6)
Polycythemia Vera (PV)
Other Hematologic Conditions
SLN548
(CFB)
CARDIOMETABOLIC
Zerlasiran
(LPA)
SLN312*
(ANGPTL3)
SLN365
(GPR146)
SLN098
(INHBE)
*SLN312 is currently licensed to AstraZeneca. As announced in a Company Press Release dated March 5, 2026, Silence will re-gain exclusive rights globally to SLN312 following Phase 1.
HoFH=Homozygous familial hypercholesterolemia